Abstract:Chunhong Li, 1, &ast Zhen Wang, 1, &ast Yifeng Zhang, 1 Yuqing Zhu, 1 Maochang Xu, 1 Hui Lei, 1 Dan Zhang 1, 2 1 Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China; 2 Green Pharmaceutical Technology Key Laboratory of Luzhou, School of Pharmacy, Southwest Medical University, Luzhou, 646000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hui Lei; Dan Zhang, Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, 1-1 Xianglin Road, Luzhou, Sichuan, 646000, People's Republic of China, Tel +86 17360593759 ; +86 18982700067, Email ; Purpose: Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer. However, the effect of current treatment strategies by inducing tumor cell apoptosis alone is not satisfactory. The growth, metastasis and treatment sensitivity of tumors can be strongly influenced by cancer-associated fibroblasts (CAFs) in the microenvironment. Effective cancer therapies may need to target not only the tumor cells directly but also the CAFs that protect them. Methods: Celastrol and small-sized micelles containing betulinic acid were co-encapsulated into liposomes using the thin-film hydration method (CL@BM). Folic acid was further introduced to modify liposomes as the targeting moiety (F/CL@BM). We established a novel NIH3T3+4T1 co-culture model to mimic the tumor microenvironment and assessed the nanocarrier's inhibitory effects on CAFs-induced drug resistance and migration in the co-culture model. The in vivo biological distribution, fluorescence imaging, biological safety evaluation, and combined therapeutic effect evaluation of the nanocarrier were carried out based on a triple-negative breast cancer model. Results: In the present study, a novel multifunctional nano-formulation was designed by combining the advantages of sequential release, co-loading of tretinoin and betulinic acid, and folic acid-mediated active targeting. As expected, the nano-formulation exhibited enhanced cytotoxicity in different cellular models and effectively increased drug accumulation at the tumor site by disrupting the cellular barrier composed of CAFs by tretinoin. Notably, the co-loaded nano-formulations proved to be more potent in inhibiting tumor growth in mice and also showed better anti-metastatic effects in lung metastasis models compared to the formulations with either drug alone. This novel drug delivery system has the potential to be used to develop more effective cancer therapies. Conclusion: Targeting CAFs with celastrol sensitizes tumor cells to chemotherapy, increasing the efficacy of betulinic acid. The combination of drugs targeting tumor cells and CAFs may lead to more effective therapies against various cancers. Keywords: liposomes, targeted delivery, triple-negative breast cancer, anti-tumor, combination therapy, sequential drug delivery Breast cancer, the most frequent cancer among women and the second most frequent newly diagnosed cancer worldwide, 1,2 remains a challenge to treat because of its heterogeneity and often aggressive behavior. 3 While efforts to develop treatments have targeted the tumor cells themselves, 4,5 recent research has discovered that the tumor microenvironment can strongly influence tumor growth, metastasis and response to treatment. 6–8 In particular, cancer-associated fibroblasts (CAFs), the most abundant cells in the stroma around the tumor, regulate tumor development by sending signals to the tumor and by altering the extracellular matrix around it. 9–11 Overexpression of α-smooth muscle actin (α-SMA) in CAFs in breast cancer can produce dense collagen secretion around blood vessels, forming a physical blockade preventing drug delivery to tumor cells. 12,13 This can lead to resistance and metastasis. Traditional therapeutic approaches that target cancer cells alone are insufficient in controlling CAF activation, resulting in recurrence and metastasis of breast cancer. 14,15 In order to improve antitumor efficacy, there is an increasing emphasis on combination therapy, ie, the use of two or more drugs with different therapeutic mechanisms to enhance antitumor efficacy through synergistic effects. 16,17 The efficacy of free drug combinations is usually compromised by insufficient bioavailability, and nanocarrier co-delivery systems are potentially advantageous in combination therapy. To date, many nanosystems have been proposed to deliver two or more molecules with synergistic pha -Abstract Truncated-

Carrier-Free Nanoagent Interfering with Cancer-Associated Fibroblasts' Metabolism to Promote Tumor Penetration for Boosted Chemotherapy

Bilayer nanocarrier with protein-acid conjugation for prolonged release and enhanced anticancer effects.

Cancer-associated Fibroblast-Targeted Nanodrugs Reshape Colorectal Tumor Microenvironments to Suppress Tumor Proliferation, Metastasis and Improve Drug Penetration

Transformable Honeycomb-Like Nanoassemblies Of Carbon Dots For Regulated Multisite Delivery And Enhanced Antitumor Chemoimmunotherapy

FNIII14 Peptide-Enriched Membrane Nanocarrier to Disrupt Stromal Barriers through Reversing CAFs for Augmenting Drug Penetration in Tumors

Prior Anti-Cafs Break Down the CAFs Barrier and Improve Accumulation of Docetaxel Micelles in Tumor.

Targeting cancer-associated fibroblasts with hydroxyethyl starch nanomedicine boosts cancer therapy

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Comprehensively Priming the Tumor Microenvironment by Cancer-Associated Fibroblast-Targeted Liposomes for Combined Therapy with Cancer Cell-Targeted Chemotherapeutic Drug Delivery System

Stromal Barrier-Dismantled Nanodrill-Like and Cancer Cell-Targeted Ph-Responsive Polymeric Micelles for Further Enhancing the Anticancer Efficacy of Doxorubicin

Reversing Activity of Cancer Associated Fibroblast for Staged Glycolipid Micelles Against Internal Breast Tumor Cells

Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy

Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells

Modulating tumor-stromal crosstalk via a redox-responsive nanomedicine for combination tumor therapy

Cancer-Targeted Controlled Delivery of Chemotherapeutic Anthracycline Derivatives Using Apoferritin Nanocage Carriers

Functionalized Nanoscale Micelles Improve Drug Delivery for Cancer Therapy in Vitro and in Vivo.

Enhanced Anticancer Efficacy of Dual Drug-Loaded Self-Assembled Nanostructured Lipid Carriers Mediated by pH-Responsive Folic Acid and Human-Derived Cell Penetrating Peptide dNP2

Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers

Extracellular Matrix Modulating Enzyme Functionalized Biomimetic Au Nanoplatform-Mediated Enhanced Tumor Penetration and Synergistic Antitumor Therapy for Pancreatic Cancer

Efficient Sequential Co-Delivery Nanosystem for Inhibition of Tumor and Tumor-Associated Fibroblast-Induced Resistance and Metastasis